BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) shares dropped 1.7% during mid-day trading on Thursday . The stock traded as low as $2.35 and last traded at $2.36, with a volume of 54,382 shares. The stock had previously closed at $2.40.

Separately, Maxim Group reiterated a “buy” rating and set a $5.00 target price on shares of BrainStorm Cell Therapeutics in a report on Wednesday, May 11th.

The stock has a 50-day moving average of $2.52 and a 200 day moving average of $2.42. The firm’s market cap is $43.84 million.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings results on Thursday, August 11th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.13. On average, equities analysts anticipate that BrainStorm Cell Therapeutics Inc. will post ($0.58) earnings per share for the current year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.